PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

国际肿瘤学杂志››2021,Vol. 48››Issue (2): 113-116.doi:10.3760/cma.j.cn371439-20200610-00022

PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

丁艳, 汪红艳()

安徽医科大学第一附属医院肿瘤放疗科,合肥 230000

收稿日期:2020-06-10修回日期:2020-06-21出版日期:2021-02-08发布日期:2021-03-11
通讯作者:汪红艳 E-mail:whhy5000@163.com
基金资助:
安徽省高校自然betway必威亚洲项目(KJ2016A341);安徽省教学研究项目(2019jyxm0994)

Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma

Ding Yan, Wang Hongyan()

Department of Radiation Oncology, First Affiliated Hospital of Anhui Medical University, Hefei 230000, China

Received:2020-06-10Revised:2020-06-21Online:2021-02-08Published:2021-03-11
Contact:Wang Hongyan E-mail:whhy5000@163.com
Supported by:
Natural Science Research Project of Colleges and Universities of Anhui Province of China(KJ2016A341);Teaching Research Project of Anhui Province of China(2019jyxm0994)

摘要/Abstract

摘要：

在亚洲食管癌确诊病例中,食管鳞状细胞癌(ESCC)占90%以上,且恶性程度高。目前针对ESCC免疫治疗的研究越来越多,尤其是关于程序性死亡蛋白-1(PD-1)和程序性死亡蛋白-配体1(PD-L1)的研究。在ESCC中研究最多的PD-1/PD-L1抑制剂主要有纳武单抗、帕博利珠单抗、卡瑞利珠单抗、特瑞普利单抗、替雷利珠单抗、阿特珠单抗、SHR-1316和度伐利尤单抗,这些药物的临床试验部分已经初步显示出良好的疗效,部分研究还在进行中。

关键词:食管肿瘤,肿瘤,鳞状细胞,PD-1,PD-L1

Abstract:

Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the confirmed cases of esophageal cancer in Asia, and the degree of malignancy is high. There is a growing number of research on ESCC immunotherapy, particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Among them, the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab, pembrolizumab, camrelizumab, toripalimab, tislelizumab, atozolizumab, SHR-1316 and durvalumab. Some of the clinical trials of these drugs are still in progress, and some have initially shown good results.

Key words:Esophageal neoplasms,Neoplasms, squamous cell,PD-1,PD-L1

丁艳, 汪红艳. PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展[J]. 国际肿瘤学杂志, 2021, 48(2): 113-116.

Ding Yan, Wang Hongyan. Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(2): 113-116.

参考文献24

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.21492pmid:30207593
[2]	Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries[J]. Thoracic Cancer, 2016,7(2):232-237. DOI: 10.1111/1759-7714.12322. doi:10.1111/1759-7714.12322pmid:27042227
[3]	Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015,348(6230):56-61. DOI: 10.1126/science.aaa8172. pmid:25838373
[4]	Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review[J]. Fukushima J Med Sci, 2018,64(2):46-53. DOI: 10.5387/fms.2018-09. pmid:30058598
[5]	Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017,18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi:10.1016/S1470-2045(17)30181-Xpmid:28314688
[6]	Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer[J]. Cancer Sci, 2020,111(5):1676-1684. DOI: 10.1111/cas.14380. pmid:32160365
[7]	Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemothe-rapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. doi:10.1016/S1470-2045(19)30626-6pmid:31582355
[8]	Yamamoto S, Kato K, Daiko H, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: frontier (JCOG1804E)[J]. Future Oncol, 2020,16(19):1351-1357. DOI: 10.2217/fon-2020-0189. doi:10.2217/fon-2020-0189pmid:32396014
[9]	Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phaseⅡ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019,19(1):231. DOI: 10.1186/s12885-019-5446-2. doi:10.1186/s12885-019-5446-2pmid:30871493
[10]	Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018,36(1):61-67. DOI: 10.1200/JCO.2017.74.9846. doi:10.1200/JCO.2017.74.9846pmid:29116900
[11]	Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019,5(4):546-550. DOI: 10.1001/jamaoncol.2018.5441. doi:10.1001/jamaoncol.2018.5441pmid:30570649
[12]	Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase Ⅲ KEYNOTE-181 study[J]. J Clin Oncol, 2019,37(4_suppl):2. DOI: 10.1200/JCO.2019.37.4_suppl.2.
[13]	Barsouk A, Rawla P, Hadjinicolaou AV, et al. Targeted therapies and immunotherapies in the treatment of esophageal cancers[J]. Med Sci (Basel), 2019,7(10):100. DOI: 10.3390/medsci7100100.
[14]	Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: Phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol, 2019,15(10):1057-1066. DOI: 10.2217/fon-2018-0609. doi:10.2217/fon-2018-0609pmid:30735435
[15]	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020,21(6):832-842. DOI: 10.1016/S1470-2045(20)30110-8. doi:10.1016/S1470-2045(20)30110-8pmid:32416073
[16]	Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study[J]. Br J Cancer, 2018,119(5):538-545. DOI: 10.1038/s41416-018-0100-3. doi:10.1038/s41416-018-0100-3pmid:29755117
[17]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi:10.1158/1078-0432.CCR-17-2439pmid:29358502
[18]	Finlay WJJ, Coleman JE, Edwards JS, et al. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement[J]. MAbs, 2019,11(1):26-44. DOI: 10.1080/19420862.2018.1550321. doi:10.1080/19420862.2018.1550321pmid:30541416
[19]	Zhang B, Wang X, Li Q, et al. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma[J]. Chin J Cancer Res, 2019,31(6):910-917. DOI: 10.21147/j.issn.1000-9604.2019.06.07. doi:10.21147/j.issn.1000-9604.2019.06.07pmid:31949393
[20]	Wang X, Zhang B, Chen X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esopha-geal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J]. Thorac Cancer, 2019,10(6):1395-1401. DOI: 10.1111/1759-7714.13083. pmid:31017739
[21]	Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. DOI: 10.1093/annonc/mdz197. doi:10.1093/annonc/mdz197pmid:31236579
[22]	Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020,26(17):4542-4550. DOI: 10.1158/1078-0432.CCR-19-3561. doi:10.1158/1078-0432.CCR-19-3561pmid:32561664
[23]	Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase Ⅱ study of Atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma[J]. BMC Cancer, 2020,20(1):336. DOI: 10.1186/s12885-020-06716-5. pmid:32312286
[24]	Guimbaud R, Quéro L, Vendrely V, et al. Prodige67_ucgi33 arion: association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: a comparative randomized phase Ⅱ trial[J]. Ann Oncol, 2019,30(suppl_5):v322. DOI: 10.1093/annonc/mdz247.163.